PRINCETON, N.J. and JINAN, China, Aug. 07, 2019 (GLOBE NEWSWIRE) — KBP BioSciences USA, a clinical stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, has entered into a Memorandum of Understanding (MOU) with BullFrog AI Inc. KBP Bioscience presently has three clinical stage compounds having obtained US FDA
Author Archives: webmaster
KBP Biosciences Co., Ltd. attended the 2017 China BioMed Innovation and Investment Conference from 29th -31st , Oct. and delivered a presentation about KBP-5074 Project at Clinical Trial Data Global First-Publishing session.
The topic is The First-Publishing of KBP-5074 Moderate to Serve Chronic Kidney Disease (CKD) and Hemodialysis Patients Data. About KBP-5074 There are about 120 million chronic kidney disease (CKD) patients among which about 18 millions are also uncontrolled hypertension patients in China, and in USA, the numbers are 24 million and 3.5 million. Clinical